Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.75 EUR
Change Today +0.048 / 1.78%
Volume 0.0
5MC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
NASDAQ CM
Stuttgart
As of 3:40 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

macrocure ltd (5MC) Snapshot

Open
€2.76
Previous Close
€2.70
Day High
€2.77
Day Low
€2.68
52 Week High
08/24/15 - €3.33
52 Week Low
08/28/15 - €2.68
Market Cap
44.4M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MACROCURE LTD (5MC)

macrocure ltd (5MC) Related Businessweek News

No Related Businessweek News Found

macrocure ltd (5MC) Details

Macrocure Ltd., a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Its lead cell-based biological product includes CureXcell, which is in two Phase III clinical trials for the treatment of hard-to-heal diabetic foot ulcers and hard-to-heal venous leg ulcers. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

28 Employees
Last Reported Date: 03/18/15
Founded in 2008

macrocure ltd (5MC) Top Compensated Officers

President and Chief Executive Officer
Total Annual Compensation: $1.2M
Chief Medical Officer
Total Annual Compensation: $375.0K
Vice President of Finance and Israeli Site Ma...
Total Annual Compensation: $219.2K
Compensation as of Fiscal Year 2014.

macrocure ltd (5MC) Key Developments

Macrocure Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Fiscal 2015

Macrocure Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported operating loss was USD 6.75 million against USD 4.4 million a year ago. Loss before income taxes was USD 6.63 million against USD 4.37 million a year ago. Loss for the period was USD 6.67 million against USD 4.4 million a year ago. Basic and diluted net loss per share was USD 0.37 against USD 0.59 a year ago. Net cash used in operating activities was USD 5.64 million against USD 4.32 million a year ago. Purchases of property, plant and equipment was USD 0.052 million against USD 0.031 million a year ago. For the six months, the company reported operating loss was USD 13.62 million against USD 7.74 million a year ago. Loss before income taxes was USD 13.49 million against USD 7.73 million a year ago. Loss for the period was USD 13.58 million against USD 7.81 million a year ago. Basic and diluted net loss per share was USD 0.74 against USD 1.05 a year ago. Net cash used in operating activities was USD 11.28 million against USD 7.26 million a year ago. Purchases of property, plant and equipment was USD 0.057 million against USD 0.106 million a year ago. The company reiterates that expected cash used for its ongoing operating activities in 2015 will be USD 21-USD 25 million, inclusive of the USD 11.5 million of cash already expended in the first half of 2015, reflecting anticipated expenditures to complete its current Phase III clinical trials in process this year. As previously disclosed, that range excludes approximately USD 4 million in potential capital expenditures in 2015 primarily related to the company's anticipated new U.S. manufacturing facility, the details for which are expected to be finalized in the second half of this year. The company expects to invest an additional USD 3 - USD 5 million to complete this facility in 2016.

Macrocure Ltd. to Report Q2, 2015 Results on Aug 04, 2015

Macrocure Ltd. announced that they will report Q2, 2015 results at 5:00 PM, Israel Standard Time on Aug 04, 2015

Macrocure Ltd., Q2 2015 Earnings Call, Aug 05, 2015

Macrocure Ltd., Q2 2015 Earnings Call, Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
5MC:GR €2.75 EUR +0.048

5MC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 5MC.
View Industry Companies
 

Industry Analysis

5MC

Industry Average

Valuation 5MC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MACROCURE LTD, please visit www.macrocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.